Atypical haemolytic uraemic syndrome (aHUS) - eculizumab: evaluation consultation

Atypical haemolytic uraemic syndrome (aHUS) - eculizumab: evaluation report

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission by the technology manufacturer - Alexion

03 - NICE request to the manufacturer for clarification on their submission

04 - Manufacturer clarification response

05 - Consultee submission - aHUS UK Part 1

06 - Consultee submission - aHUS UK Part 2

07 - Consultee submission - Kidney Research UK

08 - Consultee submission - aHUS Action Part 1 - Professional Statement

09 - Consultee submission - aHUS Action part 2 - diagnostic check list

10 - Consultee submission - aHUS Action Part 3 -Transplant protocol

11 - Consultee submission - Royal College of Physicians

12 - Consultee submission - NHS England

13 - NHSe Clinical Commissioning Policy Statement

14 - Clinical expert personal perspective - Gilbert

15 - Clinical expert personal perspective - Goodship

16 - Patient expert personal perspective - Lilley

17 - Clinical expert personal perspective - Scully

18 - Patient expert personal perspective - Woodward

19 - Evidence Review Group Report prepared by ScHARR

20 - Manufacturer factual accuracy check of Evidence Review Group report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this evaluation.

*Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *